![]() | |
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.207.983 ![]() |
Chemical and physical data | |
Formula | C27H25ClF3N3O2 |
Molar mass | 515.96 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects.[1][2] It was discovered by Merck & Co.
In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central nervous system side effects, mainly depression and anxiety.[3][4][5][6]
| |||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Phytocannabinoids (comparison) |
| ||||||||||||||||||||||||||||||||||||||||
Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||
Synthetic cannabinoid receptor agonists / neocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||
Allosteric CBRTooltip Cannabinoid receptor ligands |
| ||||||||||||||||||||||||||||||||||||||||
Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||
Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receptor (ligands) |
| ||||||||||||||||||||||||||||||
Transporter (modulators) |
| ||||||||||||||||||||||||||||||
Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||||||||
|
![]() | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |